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ABSTRACT
Objectives We aimed to calculate cumulative 
hepatitis C virus (HCV) treatment coverage among 
individuals enrolled in opioid agonist therapy (OAT) in 
Norway between 2013 and 2017 and to document the 
treatment transition to direct- acting antiviral (DAA) 
agents. Moreover, we aimed to describe adherence to 
DAAs in the same cohort.
Design Prospective cohort, registry data.
Setting Specialist healthcare service (secondary)
Participants and outcomes This observational 
study was based on data from The Norwegian 
Prescription Database. We studied dispensed 
OAT and HCV treatment annually to calculate the 
cumulative frequency, and employed secondary 
sources to calculate prevalence, incidence and HCV 
treatment coverage from 2013 to 2017, among the 
OAT population. Factors associated with adherence to 
DAAs were identified a priori and subject to logistic 
regression.
Results 10 371 individuals were identified with 
dispensed OAT, 1475 individuals of these were 
identified with dispensed HCV treatment. Annual HCV 
treatment coverage increased from 3.5% (95% CI: 3.2 
to 4.4) in 2013 to 17% (95% CI: 17 to 20) in 2017, 
giving a cumulative HCV coverage among OAT patients 
in Norway of 38.5%. A complete shift to interferon- free 
treatment regimens occurred, where DAAs accounting 
for 32% of HCV treatments in 2013 and 99% in 2017. 
About two- thirds of OAT patients were considered 
adherent to their DAA regimens across all genotypes. 
High level of OAT continuity was associated with 
improved adherence to DAAs (adjusted OR 1.4, 95% CI: 
1 to 2, p=0.035).
Conclusions A large increase in HCV treatment 
coverage attributed by a complete shift to interferon- 
free regimens among the Norwegian OAT population 
has been demonstrated. However, treatment coverage 
is inadmissibly too low and a further substantial 
scale- up in HCV treatment is required to reach the 
universal targets of controlling and eliminating the 
HCV endemic.
BACKGROUND
The large burden of chronic hepatitis C 
virus (HCV) among people who inject drugs 
(PWIDs) and recent developments in HCV 
medications creates an opportunity to elim-
inate HCV epidemics. Worldwide, about 
71 million people are chronically infected 
with the virus and 399 000 died annually 
from HCV- related complications such as 
liver cirrhosis or hepatocellular carcinoma.1 2 
Despite the low aggregated HCV prevalence 
in many countries (1.5%–3.5% in Western 
Europe and <1.5% in North America), prev-
alence is much higher among PWID (50% 
or more).3–5 WHO’s Global Health Sector 
Strategy aims to eliminate viral hepatitis as 
a public health threat by 2030.2 The even 
bolder Norwegian HCV strategy aims to 
reduce national incidence by 90% by 2023.6 
Eliminating chronic HCV requires a signifi-
cant effort in terms of increasing uptake of 
testing, diagnosing and linking to care. In 
addition, other strategies have been proposed 
alongside increasing antiviral treatment, such 
as opioid agonist therapy (OAT) scale- up, 
Strengths and limitations of this study
 ► All dispensed drugs from pharmacies in Norway are 
registered in the database.
 ► The completeness, precision and validity of data are 
high among a hard- to- reach population.
 ► Data were not linked on an individual level to diag-
nosis codes of chronic hepatitis C virus (HCV).
 ► HCV prevalence and incidence data are imprecise.
 ► Treatment with direct- acting antivirals was limited 
during the study period from 2013 to 2017 based on 
stage of liver fibrosis.
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safe injection sites and sterile injection equipment to 
reach these objectives.2 7
Injecting drug use and needle sharing is the major 
driver of HCV incidence;8 however, the coverage of 
preventive interventions, such as needle and syringe 
programmes, remains poor among PWIDs.9 Number of 
people who actively inject drugs in Norway have been 
stable at around 9000 since 2012 till 2017 (2.6 per 1000 
inhabitants aged 15–64 years),10 11 and opioids and 
amphetamines are the main injected drugs.11 12 Model-
ling studies suggest that around 7000 former and current 
PWIDs are living with chronic HCV with an estimated 
400 new cases annually in the same time period.13 14 Both 
HCV- related liver morbidity and mortality are increasing 
among PWIDs and are likely to continue to increase until 
2022.14
OAT has been put forward to play a vital role in the 
management of chronic HCV among people with opioid 
dependence and has been shown to reduce the risk of 
HCV acquisition.15 For these reasons, OAT may be crucial 
intervention for achieving large reductions in HCV trans-
missions by reducing risk behaviours such as injecting 
use and sharing of injecting equipment.16 HCV testing 
rates have been low in the national OAT programme in 
Norway with great annual and regional variations.5 17–20 
Only in parts of Western Norway, as part of the multi-
center INTRO- HCV study, all patients receiving OAT 
have been systematically tested and examined with elas-
tography as part of an annual health assessment since 
2017.21 Even if access to HCV treatment is improving, 
HCV treatment coverage remains low.8 22–25 Globally, the 
coverage of HCV curative treatment was 13% by 2016.26 
In Norway, annual HCV treatment coverage among OAT 
patients was between 1.3% and 2.6% in the period from 
2004 to 2013, giving a cumulative HCV coverage for the 
period of 14%.27
The introduction of direct- acting antiviral (DAA) medi-
cations, with a curation rate of approximately 95%, safer 
and better tolerated than interferon- based therapy, has 
dramatically changed the treatment of chronic HCV 
infections.28 29 Even if currently expensive, they are consid-
ered cost- effective from a societal perspective as universal 
coverage with antiretroviral treatment could prevent large 
expenses related to future complications.30–35 Combining 
DAAs with the OAT delivery platform may, thus, prove 
critical for achieving reductions in HCV prevalence and 
incidence.22 A number of treatment barriers exist, which 
should in turn be carefully addressed; nevertheless, treat-
ment barriers should not exclude PWIDs from HCV treat-
ment.8 36 37 Both WHO and Norwegian guidelines support 
DAA treatment among PWIDs and have also shown good 
outcomes in systematic reviews.24 25 38
The pathway to universal HCV treatment coverage has 
not been well documented at country levels; hence, the 
primary aim of the study was to:
1. Document HCV treatment annually and cumula-
tively after the introduction of DAAs among patients 
receiving OAT in Norway from 2013 to 2017 and to 
calculate HCV treatment coverage, both annually and 
cumulatively.
2. A second objective is to evaluate adherence to DAAs 
among OAT patients in Norway.
METHODS
Study design and data sources
This is an observational study among OAT patients 
from 2013 to 2017 in Norway. Data were extracted from 
The Norwegian Prescription Database (NorPD) from 
1 January 2013 to 31 March 2018. The database covers 
the entire Norwegian population and records all drugs 
dispensed from pharmacies in Norway. All drugs are clas-
sified according to The Anatomical Therapeutic Chem-
ical (ATC) classification system.39 Defined daily doses 
(DDDs) according to 201840 were employed to quantify 
the dispensed OAT and HCV medications, respectively. 
The DDDs are the assumed average maintenance dose 
per day for a drug used for its main indication.41
Data from The Norwegian Centre for Addiction 
Research were used for estimating the prevalence of 
chronic HCV among OAT patients, whereas incidence 
data among Norwegian PWIDs were gathered from The 
Norwegian Institute of Public Health and Meijerink et 
al.14
Study population and definitions
The study population included all individuals with at least 
one dispensed prescription of buprenorphine (ATC code 
N07BC01), methadone (N07BC02), buprenorphine–
naloxone (N07BC51) and levomethadone (N07BC05). 
Patients<18 years and with other indications than OAT 
were excluded from the study on the basis of formula-
tion and route of administration (online supplementary 
figure S1).
Exposure to HCV treatment was defined as being 
dispensed either pegylated interferon alpha (L03AB05 
and L03AB11) and ribavirin (J05AP01) or any of the 
DAAs (in group J05AP, see online supplementary table S1 
for complete list of DAAs by ATC code) during the study 
period. The first dispensed DAA according to ATC code 
was noted, and to prevent over- counting, patients were 
only counted once at initiation. Thus, definition of treat-
ment was any individual on OAT who has been dispensed 
HCV treatment. Any individual who died was censored 
in the calendar year they passed away. Rates were calcu-
lated by dividing number of individuals with dispensed 
HCV treatment by individuals on OAT, stratified by each 
calendar year. The cumulative frequency, which is the 
addition of successive years of treatment, was then calcu-
lated. HCV treatment was stratified as overall treatment 
with any chronic HCV medication and treatment with 
solely DAAs.
HCV treatment coverage was defined as individuals on 
OAT identified in NorPD annually, adjusted for death, 
HCV prevalence and new cases of chronic HCV each 
year, which had received treatment for chronic HCV 
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during the study period. Mean prevalence during the 
study period among patients enrolled in OAT ranged 
from 51% in 2013 to 43% in 20175 17–20 and proportional 
prevalence among OAT individuals were calculated per 
calendar year. Incidence was around 400 per year for 
PWIDs during the study period.14 It proved methodolog-
ically challenging to estimate number of new cases of 
chronic HCV among OAT patients. As the OAT coverage 
among people with opioid dependence is between 50% 
and 60% in Norway,5 OAT patients account for only a 
proportion of overall PWIDs, and thus needed to be 
adjusted for in our calculation. For this reason, expert 
opinion were obtained from clinicians in addiction medi-
cine and set to a 0.70 (70%) proportion, giving between 
277 and 256 new cases annually during the study period. 






where HCVcov is HCV coverage, tHCV=number of OAT 
patients with dispensed HCV treatment, pHCV=number of 
OAT patients with chronic HCV and iHCV=number of new 
cases of chronic HCV among OAT patients. Coverage was 
calculated annually for Norway and by Health County, 
and as cumulative frequencies.
We defined adherence to DAA as having collected 
prescriptions equivalent to 3 months of treatment. DAAs 
for adults, which is only prescribed by specialists, are 
collected for 1 month at- a- time basis where a typical DAA 
treatment course is 12 weeks, that is, 3 dispensed prescrip-
tions and ≥84 DDDs. The exception is the drug combi-
nation ledipasvir/sofosbuvir, which may be prescribed 
for 8 weeks (two collections and ≥56 DDD) for cases of 
previously untreated genotype 1 infections. This allowed 
us to examine adherence based on number of dispensed 
prescriptions and DDDs. Impending factors associated 
with treatment adherence to DAAs were identified a 
priori and included gender, age and OAT continuity, and 
subject to multivariate analyses in a step- by- step model.
Finally, OAT continuity was defined according to 
dispensed DDDs and stratified into three categories, 
ranging from a high level of OAT continuity in category 
I (≥2 DDD), medium in category II (1–2 DDD) and to 
a low level of OAT continuity in category III (<1 DDD). 
One DDD for methadone and buprenorphine is 25 and 
8 mg, respectively.
Statistical analyses and strategy
Descriptive data are presented as frequencies, percent-
ages, means and with corresponding 95% confidence 
intervals where appropriate. Logistic regression on 
factors associated with adherence is presented as adjusted 
OR when adjusted for age, gender and OAT continuity.
The data were analysed with SPSS V.24 and Stata SE 
V.15 (StataCorp, Texas, USA). Map figures were made in 
R.
Data handling and ethical considerations
Since all registry data were received pseudo- anonymously 
from the registry administrator and subsequently anal-
ysed anonymously no written consent was obtained from 
any of the individuals in the study.42
Patient and public involvement
No patients were directly involved in this study; however, 
as part of the bigger Integrated treatment of hepatitis 
C (INTRO- HCV) project patients through user organi-
sations, such as Pro- LAR, were involved in the planning 
process, workshops that included design and recruit-
ment, protocol writing and assessment of the burden of 
the intervention in the randomised controlled trial.
RESULTS
Basic characteristics of study population
A total of 10 371 individuals were identified in NorPD 
having received ≥1 OAT prescriptions during the study 
period from 2013 to 2017 (table 1). Almost 70% were men, 
mean age of 43 and 45 years in 2013 and 2017, respec-
tively. The majority of the OAT patients were treated with 
buprenorphine- based OAT medication (55% in 2013 and 
61% in 2017). Over 50% of individuals on OAT had a 
high level of continuity. Altogether, 692 individuals died 
during the study period.
HCV treatment and coverage
HCV and DAA treatment
All individuals were stratified according to the year in 
which they received OAT and HCV treatment. Excluding 
deaths, this gave a fairly stable OAT population just in 
excess of 7500 annually. In 2013, 146 OAT patients 
received HCV treatment. Treatment increased over 
time with 597 patients receiving HCV treatment in 2017. 
Overall, 1475 patients on OAT received HCV treatment 
during the study period, with an annual HCV treatment 
increasing from 1.9% (95% CI: 1.6 to 2.3) in 2013 to 7.9% 
(95% CI: 7.3 to 8.5) in 2017 (online supplementary table 
S2). By 2017, the cumulative frequency of HCV treatment 
reached 19% among patients on OAT.
Of the 1475 individuals who received HCV treatment 
during the study period, 1235 were treated with DAAs. 
The annual DAA treatment ranged from 0.6% (95% CI: 
0.4 to 0.8) in 2013 to 7.8 (95% CI: 7.2 to 8.4) in 2017. 
The proportion of treated individuals receiving DAAs 
increased over time from 32% of HCV- treated OAT 
patients in 2013 to 99% in 2017.
HCV treatment: coverage
We calculated annual HCV coverage among the estimated 
number of OAT patients who are HCV infected, which 
ranged from 3.5% (95% CI: 3.2 to 4.4) in 2013 to 17% 
(95% CI: 16.9 to 19.6) in 2017. This gave a cumulative 
frequency that reached 38.5% in 2017 (table 2). Figure 1 
shows cumulative HCV coverage from 2013 to 2017 by the 
four health counties in Norway (HCVcov and data from 
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online supplementary table S3 were used for these calcu-
lations). There were little variation in treatment coverage 
across the four health counties.
Adherence to DAAs
Overall, almost 70% of the OAT patients were adherent to 
their DAA regimen and considered to have finished their 
DAA treatment course (table 3). There were no major 
differences by gender or OAT drug. However, for age, 
patients in the age group 18–35 were less adherent (42%) 
compared with older age groups. The drug combination 
of elbasvir/grazoprevir, commonly used for treatment of 
genotype 1 infections, had by far the utmost adherence 
(93%) compared with treatment combinations of sofos-
buvir/velpatasvir and ledipasvir/sofosbuvir, which both 
were around 70%. However, sometimes ledipasvir/sofos-
buvir is prescribed for 8 weeks, in which case yields an 
overall adherence of 78%.
In multivariate analyses, only OAT continuity was asso-
ciated with adherence to DAAs (adjusted OR 1.4, 95% CI: 
1.0 to 1.8, p=0.035).
DISCUSSION
The HCV treatment coverage has increased substantially, 
yet it seems too low if the ambitious targets of ending the 
endemic are to be met. Annual treatment rate increased 
from 1.9% of all OAT patients in Norway in 2013 to 7.9% 
in 2017, which gives a cumulative frequency of around 
19% over the study period. However, cumulative HCV 
treatment coverage among OAT patients with assumed 
chronic HCV in Norway was just above 38%, with annual 
treatment coverage that ranged from 3.5% in 2013 to 17% 
in 2017. Second, we observed a complete shift in the HCV 
treatment among OAT patients in Norway during the 
study period, from two- thirds treated with DAAs in 2013 
to nearly all in 2017. Finally, about two- thirds of all OAT 
patients with chronic HCV were considered adherent to 
their DAAs regimen, which improved with level of OAT 
continuity.
It can be useful to compare our results at country 
levels. Immense advances have been made in chronic 
HCV treatment since the introduction of DAAs in recent 
years; however, multiple studies have demonstrated 
continued low treatment uptake among PWIDs and OAT 
patients,23 27 43 partly explained by varying and restricted 
treatment access policies that prevented a widespread 
scale- up of DAA treatment during the study period.44 For 
instance, England saw one of the most restricted access 
policies to DAA treatment compared with for example 
France and Germany, which had the least restrictions.45 
Consequently HCV treatment rates varied dramatically 
across European countries ranging from 0.6% to 10.2% 
in 2015.46 In the same year, we found HCV treatment rate 
of 5.6% in Norway, which is similar to Sweden; however, 
higher than Denmark that saw treatment rate more in 
line with the overall 3.7% that year among European 
Table 1 Basic characteristics of patients receiving OAT from 2013 to 2017 in Norway
Basic characteristics Total 2013 2014 2015 2016 2017
Individuals>1 OAT 10 371 7709 7914 7958 7804 7709
Deaths 692 165 151 138 114 124
Gender, n (%)
  Male 7135 (69) 5221 (69) 5390 (69) 5430 (69) 5354 (70) 5254 (69)
  Female 3236 (31) 2323 (31) 2373 (31) 2390 (31) 2336 (30) 2340 (31)
Age, n (%)
  <25 211 (3) 185 (2) 171 (3) 135 (2) 120 (2)
  26–40 2813 (37) 2797 (36) 2718 (40) 2574 (33) 2432 (32)
  41–60 4289 (57) 4537 (58) 3644 (53) 4627 (60) 4613 (61)
  >60 231 (3) 244 (3) 287 (4) 354 (5) 420 (6)
OAT medication, n (%)
  Methadone/levomethadone 3406 (45) 3264 (42) 3216 (41) 3066 (40) 2981 (39)
  Buprenorphine based* 4138 (55) 4499 (58) 4604 (59) 4624 (60) 4604 (61)
  Dispensions of HCV drugs† 1475 146 167 243 322 597
OAT continuity category, n (%)
  I: ≥2 DDD 5310 (51)
  II: 1–2 DDD 3078 (30)
  III: <1 DDD 1983 (19)
*Buprenorphine and buprenorphine/naloxone.
†HCV drugs: interferon- based and DAAs.
DDDs, Daily defined Doses; HCV, hepatitis C virus; NorPD, Norwegian prescription database; OAT, opioid agonist therapy.
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countries.46 Prior to the introduction of DAAs, Midgard 
et al showed an annual treatment coverage of 1.3%–2.6% 
between 2004 and 2013 among Norwegian OAT patients, 
giving a cumulative treatment coverage of 14% during 
the entire study period. Considering there is not in place 
a national and systematic programme for testing and 
linking to HCV care among PWIDs, nor has the full effec-
tiveness of integrated treatment combining OAT and 
HCV treatment been fully demonstrated,47 HCV coverage 
would probably be substantially higher with a compre-
hensive model of integrative care where both testing and 
treatment were provided in OAT outpatient clinics.
The Norwegian hepatitis C policy identifies improved 
access to treatment, prevention and surveillance of the 
endemic as crucial to succeed with HCV elimination 
strategies.48 Treatment with DAAs in Norway was until 
1 February 2018, limited by eligibility criteria based on 
stage of liver fibrosis. Since then, DAA treatment has 
been offered to all regardless of genotype and level of 
liver fibrosis. As a result, treatment demand increased and 
coverage of curative HCV treatment has amplified. From 
2014 to June 2018, around 5000 patients were treated 
for chronic HCV in Norway; however, these patients are 
mostly former PWIDs and immigrants being infected 
prior to the arrival in Norway.13 It is unclear how many 
of these patients were on OAT and overlapped with our 
results. Nonetheless, despite continued falling prices of 
DAAs, which have made unrestricted treatment possible 
for all, HCV treatment and coverage remains low among 
active PWIDs,13 which is in line with our results demon-
strating the need for a significant scale- up to improve 
HCV coverage and being able to plan elimination strate-
gies. It may, therefore, be crucial to identify other barriers 
to treatment for this vulnerable patient group. Arguably, 
even with DAA treatment for all, low threshold OAT, 
needle and syringe programmes in place, it is hard to see 
how this can be achieved unless testing and linkage to 
care is provided where PWIDs and OAT patients actually 
are. This opts for decentralised testing and treatment 
and probably a change in how the specialist healthcare 
delivers treatment for current PWIDs. A substantial 
scale- up in DAA treatment requires Norway’s capacity 
and health system infrastructure at large, in addition 
to take place among this group of patients, which have 
the highest transmission risk in order for treatment- as- 
prevention strategies to succeed. In terms of surveillance, 
chronic HCV prevalence and incidence data are not 
readily available for Norway. The infection is regarded as 
a Group A infectious disease and it has been mandatory to 
notify The Norwegian Surveillance System for Communi-
cable Diseases (MSIS) since 1990. However, only cases of 
acute HCV were notifiable initially. Since 1 January 2016 
Table 2 Annual and cumulative chronic HCV treatment coverage among OAT patients in Norway between 2013 and 2017
Source 2013 2014 2015 2016 2017 Total
Chronic HCV treatment, n 
(overall)
NorPD 146 167 243 322 597 1475
DAAs, n NorPD 46 95 212 290 592 1235
DAAs, % of HCV   32 57 87 90 99 84
Study population, n, 
yearly including deaths
NorPD 7709 7914 7958 7804 7709 10 371
Deaths NorPD 165 151 138 114 124 692
Study population, n, 
yearly, excluding deaths
NorPD 7544 7763 7820 7690 7585 9679
Prevalence chronic HCV, 
mean %
SERAF 51 52 52 46 43
Prevalence chronic HCV, 
n
SERAF 3847 4037 4066 3537 3262




396 388 381 374 366
Incidence chronic HCV 
OAT from PWIDs, n
Expert opinion 277 272 267 262 256
Treatment coverage 
chronic HCV, %
  3.5 3.9 5.6 8.5 17
Cumulative frequency 
chronic HCV
  3.5 7.4 13 21.5 38.5
95% CI treatment 
coverage chronic HCV









DAA, direct- acting antivirals; ; HCV, hepatitis C virus; NIPH, Norwegian Institute for Public Health; NorPD, Norwegian Prescription Database; 
OAT, opioid agonist therapy; ;PWID, people who inject drugs; SERAF, The Norwegian Centre for Addiction Research.
 on O









pen: first published as 10.1136/bm





6 Aas CF, et al. BMJ Open 2020;10:e036355. doi:10.1136/bmjopen-2019-036355
Open access 
it was changed to merely include HCV RNA and HCV 
core antigen.13 Thus, it is impossible to tell whether cases 
before 2016 were acute or chronic, or whether patients 
achieved sustained virological response (SVR) on their 
own, or how many cases were actually notified.27
About two- thirds of all patients were considered 
adherent to the DAA regimens. At first, this may seem 
low; however, this may be related to patients being cate-
gorised as adherent (100%) and non- adherent (<100%) 
according to recommendations from the prescribing 
specialist. For instance, the SIMPLIFY study, while demon-
strating that 97% of PWIDs completed DAA treatment, 
overall 32% were considered non- adherent (<90% adher-
ence) with median adherence at 94%.49 Another study 
among PWIDs and OAT patients, were 97% completed 
DAA treatment, found a non- adherence of 40% (<90%) 
and median adherence at 92%.50 Other studies have 
shown that high adherence to DAAs is achievable with 
appropriate supportive strategies.51 52 As such, adherence 
can be a key predictor for response to DAAs.51 Perhaps 
the most compelling evidence among PWIDs and OAT 
patients is a recent systematic review that showed DAA 
completion rate of above 97% among almost 4500 partic-
ipants.53 Our intention was to evaluate to what extent 
patients initiated and complied to treatment, rather 
than drawing a comparison between individual DAAs. 
The main reason for this is varying adherence to drug 
protocol and guidelines for DAAs during the study period 
from a prescriber’s perspective, which was only moderate 
after introduction of DAAs, although it increased mark-
edly after 2015.54 In addition, since included patients 
were only counted once on DAA initiation, there is some 
uncertainty whether patients in the non- adherent group 
had lengthier treatment courses due to for instance 
awaiting liver transplantation or becoming reinfected 
with HCV. Rate of reinfection is controversial and less 
understood; however, it seems to be low between 1% 
and 5% in the interferon era.55 After the introduction 
of DAAs, a study found six cases of reinfection among 
301 patients (4.6 reinfections per 100 person- years), with 
three of those experiencing spontaneous clearance of 
their reinfection.56
Adherence to DAAs was associated with OAT continuity, 
and as such, predicted a higher adherence compared with 
lower level of OAT continuity in our model. Studies have 
shown that patients receiving higher doses of OAT, for 
example methadone, above 60 mg/day, have better treat-
ment outcomes compared with lower doses48 57 and for 
this reason we set high level of continuity above two DDD. 
This is in line with previous studies demonstrating that 
OAT continuity is a factor for HCV treatment.27 Age was 
not considered statistical significant; however, less adher-
ence was noted in the younger age groups. Dissimilarities 
in methodology and study settings, however, prevent for 
precise comparisons of adherence, including the above. 
Linking these data, on an individual level, to biomarkers 
of SVR12 was, however, beyond the scope of this paper. In 
addition, we had no system in place to control whether 
these patients actually swallowed and metabolised these 
drugs and as such cannot comment to the extent the 
medications were actually taken.
Figure 1 Cumulative chronic HCV treatment coverage among OAT patients, from 0 (white) to 100% (black) in Norway 
between 2013 and 2017 by health counties*. Meijerink et al 14 (2017) calculations in online supplementary table S2 *Cumulative 
coverage in %, the four health counties: Helse Vest, Helse Midt, Helse Nord and Helse Sør-Øst. OAT, opioid agonist therapy; 
HCV hepatitis C virus. NorPD, Norwegian Prescription Database; SERAF, The Norwegian Centre for Addiction Research; NIPH, 
Norwegian Institute for Public Health.
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Strengths and limitations
All dispensed drugs from pharmacies in Norway are regis-
tered in NorPD. This provide researchers and other stake-
holders alike with sound, precise and a near complete 
database. The main strength of the study is, thus, it provides 
a large sample of hard- to- reach patients being treated for 
chronic HCV.
However, this study has some limitations, which should 
be considered when interpreting both results and conclu-
sions. Treatment with OAT in Norway is not uniform. It is 
estimated that NorPD captures around 90% of the patients 
with dispensed OAT from pharmacies.5 The 10%, which is 
not included in our study, could represent OAT patients with 
more need for follow- up in the OAT outpatient clinics, and 
as such, can represent patients with higher disease burden 
and in need of HCV treatment. This could skew our results 
toward underestimating the HCV treatment coverage as 
these patients would not be included in our study. On the 
other hand, our estimates can also be overestimates. OAT 
patients have successfully entered the healthcare system, and 
therefore more likely to accept other medical care, including 
HCV treatment, and thus bias our results toward improved 
HCV treatment coverage.
OAT and HCV treatment administered to hospitalised 
and institutionalised patients are not recorded on an indi-
vidual level in NorPD. Nonetheless, it should be stated that 
almost all HCV treatment is initiated in outpatient clinics in 
Norway, and hence included in NorPD.27 58 In addition, some 
dispensed prescriptions may lack reimbursement codes and 
medical indication for use, and DDDs does not necessarily 
reflect the prescribed daily dose.
Furthermore, data were not linked on an individual level 
to diagnosis codes of chronic HCV. This is due to the quality 
of MSIS prior to 2016 is poor and the authors had to employ 
other data sources when estimating HCV prevalence and inci-
dence rates from a number of different sources, including 
modelling and expert opinion. This could lead to either 
overestimating or underestimating the HCV coverage. We 
believe, however, that the 0.7 (70%) proportion represents a 
liberal estimate and the biggest risk is that we overestimated 
Table 3 Adherence* to DAAs among OAT patients in Norway between 2013 and 2017
Adherent Non- adherent Total
Adherence by gender, n (%)
  Male 551 (67) 277 (33) 828
  Female 191 (67) 92 (33) 283
  Total 742 (67) 369 (33) 1111
Adherence by age, n (%)
  18–35 119 (58) 85 (42) 204
  36–45 259 (68) 122 (32) 381
  46–55 302 (70) 128 (30) 430
  >56 62 (65) 34 (35) 95
  Total 742 (67) 369 (33) 1111
Adherence by OAT medication, n (%)
  Methadone/levomethadone 298 (65) 157 (35) 455
  Buprenorphine based 444 (68) 212 (32) 656
  Total 742 (67) 369 (33) 1111
Logistic regression on factors associated with adherence*
  aOR (CI 95%) P value
Age 0.98 (0.97 to 1.00) 0.17
Gender
  Male 1.00   
  Female 0.92 (0.69 to 1.23) 0.57
OAT continuity
  Category I: ≥2 DDD 1.00   
  Category II: 1–2 DDD 1.36 (1.02 to 1.82) 0.035
  Category III: <1 DDD 1.36 (0.93–1.99) 0.11
*Adherence defined as collected ≥3 prescriptions and >84 DDDs (unless ledipasvir and sofosbuvir which also calculated as ≥2 prescriptions 
and >56 DDDs). Analyses included 1111 patients as inclusion were ceased 01.10.17 to avoid counting treatment initiation after this date non- 
adherent.
DAA, direct- acting antivirals; DDD, daily defined doses; NorPD, Norwegian Prescription Database; OAT, opioid agonist therapy.
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the HCV incidence. When calculating the HCV prevalence, 
mean population data for Norway were used, rather than 
more accurate regional data as the latter were not readily 
available. In addition, treatment with DAAs was limited by 
stage of liver fibrosis during the study period. Only from 1 
February 2018, it was offered universally regardless of level 
of liver fibrosis. Thus, it is likely that younger patients and 
patients with Metavir F0–F1 Score were excluded from DAA 
treatment during the study period.
When measuring adherence among different age groups, 
we should be careful when interpreting results. Older 
patients are more likely to have cirrhosis and longer HCV 
treatment courses compared with younger patients. This 
could bias our results toward higher adherence among the 
latter. Finally, PWIDs are a heterogenic group of individuals, 
and one should be careful not to generalise OAT patients to 
include all PWIDs.
CONCLUSION
This is the first population- based study documenting the 
transition to DAA treatment regimens among Norwe-
gian OAT patients. A marked scale- up in HCV treatment 
coverage attributed by a complete shift to interferon- free 
regimens among Norwegian OAT patients has been demon-
strated. Adherence to DAAs across all genotypes remained 
sound, especially for high level of OAT continuity. Annual 
HCV treatment coverage ranged from 3.5% in 2013 to 17% 
in 2017, giving a cumulative HCV coverage among OAT 
patients for the study period just above 38%. Despite a large 
increase in treatment, overall HCV coverage is inadmissibly 
too low in order to meet the ambitious national and WHO 
targets of controlling and eliminating chronic HCV. There 
is a need to establish more accurate monitoring system and 
more precision in prevalence and incidence rates of chronic 
HCV among PWID to get more precise coverage data. Effi-
cacy of health system strategies is needed in order to further 
scale- up of the most effective HCV policies to this group and 
for countries to be able to control and eliminate HCV.
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